Cytek Biosciences (CTKB) Gains from Investment Securities (2022 - 2026)

Cytek Biosciences' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• Quarterly Gains from Investment Securities rose 15.94% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (up 1.22% YoY) and the FY2025 annual result came in at -$5.7 million, down 8.87% from the prior year.
• Gains from Investment Securities was -$1.3 million for Q1 2026 at Cytek Biosciences, down from -$1.2 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at -$77000.0 in Q4 2022 and bottomed at -$2.1 million in Q2 2023.
• A 5-year average of -$1.3 million and a median of -$1.4 million in 2023 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 1712.99% — and 2024, when it soared 44.3%.
• Cytek Biosciences' Gains from Investment Securities stood at -$77000.0 in 2022, then tumbled by 1712.99% to -$1.4 million in 2023, then slipped by 13.18% to -$1.6 million in 2024, then climbed by 23.29% to -$1.2 million in 2025, then retreated by 3.55% to -$1.3 million in 2026.
• Business Quant data shows CTKB's Gains from Investment Securities at -$1.3 million in Q1 2026, -$1.2 million in Q4 2025, and -$1.4 million in Q3 2025.